Pembrolizumab with salvage chemotherapy for Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have classical Hodgkin lymphoma confirmed by biopsy (tissue testing).
- Your disease is either your first relapse, or it did not respond to initial treatment.
- Your diagnosis is not nodular lymphocyte-predominant Hodgkin lymphoma.
- Your diagnosis is not a composite lymphoma type.
- You must be eligible for the study’s combination treatment approach with pembrolizumab and salvage chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (anti-PD-1 antibody) and radiation therapy for people with newly diagnosed, early-stage classic Hodgkin lymphoma that does not have certain risk factors. The goal is to see if this approach works well and has fewer side effects.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This trial studies whether adding zimberelimab (an immune system drug) to standard AVD chemotherapy works better for newly diagnosed early-stage Hodgkin lymphoma. It may help improve control of the cancer, especially when it can’t be fully cured with simpler treatment alone.
This trial tests pembrolizumab as a first treatment for advanced classical Hodgkin lymphoma. It may help patients who have not received any prior therapy.
This Phase 2 study tests azacitidine together with pembrolizumab in people whose Hodgkin lymphoma has come back or did not respond (relapsed/refractory). It aims to see whether this combination can control cancer and improve outcomes, especially when standard high-dose chemotherapy is not an option.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.